Epardex

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Epardex

Quick Facts

Property Description
Active ingredient Diclofenac (as sodium or potassium salt)
Form Tablet (often enteric-coated), Capsule, Oral Solution Powder
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Systemic relief of pain and inflammation
Origin Synthetic benzeneacetic acid derivative

Epardex is a pharmaceutical preparation containing the active substance Diclofenac, which is officially classified as a potent Nonsteroidal Anti-inflammatory Drug (NSAID) used for systemic relief. As a synthetic compound, Diclofenac belongs to the benzeneacetic acid derivative chemical family, a characteristic that defines its distinct structure compared to other common NSAIDs. The medication is recognized as both an analgesic and a significant anti-inflammatory agent for the symptomatic management of pain.


What Pharmacological Class Does Epardex Belong To?

Epardex primarily belongs to the NSAID class, functioning specifically as a Prostaglandin Synthesis Inhibitor. This mechanism means the medicine acts by reducing the production of prostaglandins, which are key chemical messengers that trigger the symptoms of inflammation, pain, and fever. Diclofenac functions as an inhibitor of cyclooxygenase enzymes, which is the biological target for its systemic effects. This action provides relief by directly interfering with the biochemical pathways responsible for pain signaling and swelling.


What is the Composition and Form of Epardex?

The composition of Epardex centers on the sole active ingredient, Diclofenac, typically formulated as the stable sodium or potassium salt. The medication is most commonly supplied for oral administration as a tablet. Many forms are specifically designed as an enteric-coated tablet, a key feature intended to protect the stomach lining by ensuring the drug bypasses gastric acid and dissolves safely in the small intestine. This structural design for oral delivery is essential for its systemic action, classifying Epardex as a single active ingredient product.

What side effects are possible with Epardex?

Serious Adverse Reactions and Risk Information

Epardex carries an official Boxed Warning regarding the risk of serious, potentially fatal Cardiovascular (CV) Thrombotic Events and serious, potentially fatal Gastrointestinal (GI) Adverse Events.


Cardiovascular and Gastrointestinal Risks

Cardiovascular Thrombotic Events

  • Use may increase the risk of serious CV thrombotic events, including myocardial infarction (MI) and stroke. This risk may occur early in treatment and may increase with the duration of use and higher doses.
  • Epardex is contraindicated (must not be used) in the setting of Coronary Artery Bypass Graft (CABG) surgery and in patients with established cardiovascular disease (e.g., congestive heart failure [NYHA class II-IV], ischemic heart disease, peripheral arterial disease, or cerebrovascular disease).

Gastrointestinal Adverse Events

  • NSAIDs, including Epardex, can cause serious GI inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, or intestines, which can be fatal. These events can occur without warning symptoms.
  • The risk of serious GI events is higher for elderly patients and those with a prior history of GI bleeding or peptic ulcer disease.

To minimize potential risk, the lowest effective dose should be used for the shortest duration possible.


Other Clinically Significant Adverse Reactions

Other adverse reactions documented in regulatory sources include hepatotoxicity (liver test abnormalities, potentially leading to liver failure), renal toxicity (kidney dysfunction and hyperkalemia), hypertension, heart failure and edema, and hematologic toxicity (e.g., anemia).

Hypersensitivity: Severe, sometimes fatal, allergic reactions (anaphylaxis) and serious skin reactions (e.g., Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis) have been reported. Epardex is contraindicated in patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.

Pregnancy: Use is advised against starting at about 20 weeks gestation due to the risk of fetal renal dysfunction and is contraindicated from 30 weeks gestation onward due to the risk of premature closure of the fetal ductus arteriosus.

Common Adverse Reactions (most frequently reported in clinical trials) include abdominal pain, diarrhea, dyspepsia, nausea, flatulence, gastritis, vomiting, headache, and dizziness.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents state that an overdose of Epardex (Diclofenac) requires immediate emergency attention. Individuals must seek medical help right away and contact emergency services or a poison control center immediately if an overdose is suspected. This is a mandatory action due to the potential for severe complications documented in the labeling.

Common manifestations documented in regulatory labeling include gastrointestinal effects such as nausea, vomiting, diarrhea, and stomach pain. Neuro-sensory effects are also commonly listed, presenting as dizziness, headache, confusion, or ringing in the ears (tinnitus).

The overdose profile highlights the potential for serious, life-threatening systemic outcomes. These include acute renal failure, severe gastrointestinal complications such as bleeding and perforation, and an increased risk of arterial thrombotic events like myocardial infarction and stroke. Elderly patients are noted in official labeling as being at a greater risk for serious gastrointestinal events.

Regulators confirm that no specific antidote is known for Diclofenac overdose. Management is therefore focused entirely on symptomatic and supportive care measures. For patients who ingested a large dose within a short period, procedural steps such as the administration of activated charcoal may be considered by healthcare professionals. Hospital monitoring of vital signs and laboratory parameters is required to manage documented toxicity.

Therapeutic Uses of Epardex

What Epardex Treats: Main Uses and Benefits

Epardex (Diclofenac) is generally used across domains where additional symptomatic support is needed for symptoms related to physical discomfort and inflammatory states. The medicine is relevant in contexts marked by increased discomfort or tension, and generally helps address symptoms that interfere with daily comfort. The medication may be used to help with pain, tenderness, swelling, and stiffness caused by various forms of arthritis.

The medicine is commonly used across conditions presenting with acute episodes and those involving episodic or fluctuating manifestations. It is considered relevant for easing symptoms associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gout flare-ups, musculoskeletal injuries, post-procedural discomfort, acute migraine attacks, and symptoms related to systemic imbalance such as fever. The medicine assists in easing the overall symptom burden linked to pain and inflammation, providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Joint Pain The medicine is applied when appropriate for managing symptoms that interfere with daily comfort and may help patients cope more steadily with symptom fluctuations in conditions where functional stability becomes affected.

Regulatory References

  1. Diclofenac: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Epardex (a systemic non-steroidal anti-inflammatory drug or NSAID) is subject to strict governmental regulatory rules regarding patient eligibility, primarily due to established cardiovascular and gastrointestinal risks.

Populations for Whom Use is Prohibited (Contraindicated)

The medicine is formally contraindicated and must not be used by patients who have an established history of:

  • Ischaemic Heart Disease (e.g., history of heart attack or angina).
  • Peripheral Arterial Disease.
  • Cerebrovascular Disease (e.g., history of stroke).
  • Congestive Heart Failure (New York Heart Association [NYHA] classification II–IV).
  • Hypersensitivity (allergic-type reactions, such as asthma or hives) to Epardex, aspirin, or other NSAIDs.
  • Perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Eligibility Requiring Special Consideration

Use is not recommended in the third trimester of pregnancy (starting at 30 weeks gestation) due to risk to the fetus. For patients with significant cardiovascular risk factors (e.g., uncontrolled high blood pressure, diabetes, smoking), treatment should only be initiated after careful medical consideration, using the lowest effective dose for the shortest possible duration.

  • Age: Safety and effectiveness for systemic use in children under 12 years of age is generally not established. Elderly patients may require caution due to increased risk of kidney or stomach problems.
  • Condition: Use is also generally avoided in patients with active gastrointestinal bleeding or severe kidney impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Epardex (Diclofenac) documents several clinically significant interactions involving both additive risks and pharmacokinetic alterations with co-administered substances.

Formally Documented Contraindicated Combinations

Classification Restricted Context or Substance
Procedural Restriction Use in the setting of perioperative pain for Coronary Artery Bypass Graft (CABG) surgery [FDA].
Allergy-Related Co-administration with Aspirin or other NSAIDs in patients with known aspirin-sensitive asthma or related allergic-type reactions [FDA].

Pharmacokinetic and Pharmacodynamic Interactions

Official labeling identifies several drug classes that interact, often by increasing toxicity or reducing clearance of the co-administered agent:

  • Increased Bleeding Risk: Co-administration with Anticoagulants (e.g., Warfarin), Antiplatelet agents, SSRIs, and Oral Corticosteroids is officially documented to increase the risk of serious gastrointestinal bleeding [DailyMed].
  • Clearance Inhibition: Epardex inhibits the clearance of Lithium and Methotrexate, which results in the elevation of their plasma levels (AUC) and potential toxicity [DailyMed]. Strong CYP enzyme inhibitors like Voriconazole are also noted to increase Epardex's own systemic exposure [FDA].
  • Antagonism of Effect: Concomitant use with ACE Inhibitors, ARBs, and Diuretics may diminish the blood pressure or fluid-management effect of these medicines [DailyMed].

Population-Specific and Substance Notes

  • Elderly or Renally Impaired: The combination with ACE Inhibitors or ARBs may result in a deterioration of renal function in elderly, volume-depleted, or renally impaired patients [FDA].
  • Alcohol: Ingestion of alcohol officially increases the risk of gastric irritation and gastrointestinal mucosal bleeding [MedlinePlus].
  • Other NSAIDs: Co-administration with other oral NSAIDs (e.g., Ibuprofen, Naproxen) is officially restricted due to the cumulative and increased risk of serious adverse events [DailyMed].

Mechanism of Action

Epardex (Diclofenac) exerts its action through two primary, complementary mechanistic domains: the reduction of chemical mediator synthesis and influence on peripheral neural pathway activity.


Inhibiting Synthesis of Inflammatory Mediators

The drug's core mechanism involves acting as a competitive inhibitor of the Cyclooxygenase (COX) enzymes (COX-1 and preferentially COX-2). By blocking these enzymes, Epardex limits the Arachidonic Acid Cascade, thereby reducing the synthesis of prostanoid chemical mediators, particularly Prostaglandin E2 (PGE2). This molecular action is essential for damping the physiological processes associated with localized inflammatory responses and the sensitization of peripheral nociceptors.


Modulating Peripheral Nociceptive Activity

In addition to its action on inflammatory mediator pathways, Epardex engages mechanisms that directly influence nociceptive signaling. This is achieved by modulating the function of ATP-sensitive potassium channels ( K ATP channels) on peripheral sensory neurons and reducing the local release of neuropeptides involved in nociception like Substance P. This cellular stabilization increases the depolarization requirement for action potential generation, thereby contributing to the dampening of inflammatory and nociceptive pathway activity.

Dosage and Administration Information

How to Use Epardex — Official Administration Guidelines

Epardex (Diclofenac) administration follows specific protocols established by regulatory authorities, which mandate precise methods for dosing, frequency, and preparation.


Administration Scope

Entity Detail
Route of administration The medicine is officially approved for Oral (tablet, capsule, powder), Topical (gel, solution), and Rectal use. Intramuscular and intravenous routes are reserved for controlled clinical settings.
Dosing schedule For chronic conditions, adult oral doses typically range from 100 mg/day to 150 mg/day in divided doses (e.g., 75 mg twice daily or 50 mg three times daily). The oral powder form for acute use is a single 50 mg dose.
Timing in relation to meals The oral solution powder must be taken on an empty stomach to optimize absorption kinetics. Enteric-coated tablets may be taken with food, although this action may delay the onset of drug absorption.
Preparation requirements Oral solution powder must be mixed with 1 to 2 ounces (30 to 60 mL) of water only and consumed immediately after mixing. Delayed-release and extended-release tablets must always be swallowed whole and must not be crushed, cut, or chewed.

Official Use Constraints

The fundamental principle for all systemic formulations is to use the lowest effective dosage for the shortest duration possible, consistent with individual treatment goals. Treatment for older adults should be initiated with the lowest available dose. Different oral forms, such as immediate-release tablets and oral powders, may not be bioequivalent and should not be interchanged without guidance. Topical formulations must be applied only to clean, intact skin, with instructions to avoid sun exposure on the treated area.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Proposed Target Studies

Studies have described the agent's proposed target, involving a specific inflammatory pathway. Early, non-clinical models explored the potential for a change in flare frequency.

Key Clinical Trial Findings

One large-scale Phase III trial evaluated changes in patient-reported symptoms over a 12-week period. The trial's primary endpoint measured the percentage of participants who achieved a defined improvement threshold.

Additional analyses focused on secondary endpoints, which included measures of systemic inflammation (such as C-reactive protein levels). Research investigated this treatment's influence on pain and its relationship with inflammatory damage.

  • Study Design: The majority of the foundational research comes from randomized, placebo-controlled trials (RCTs).
  • Duration: Outcomes were primarily measured over short- to medium-term periods (up to 6 months). Longer-term observational studies continue to investigate outcomes up to two years.

Comparative Research

One study compared combination therapy with Drug B to monotherapy. This open-label trial analyzed differences in symptom scores between the two groups after 24 weeks. Results of this comparison are available for review.

Further exploratory research has examined whether studies of the drug's administration route affected key outcomes.

Safety and Side Effects Data

The most common side effects reported in studies include temporary injection site reactions, headache, and mild gastrointestinal upset.

Emerging Data and Future Research

Early research explored the relationship between Drug C and long-term joint function in participants with chronic disease. These preliminary findings require further investigation.

The current formulation was studied using less frequent dosing than prior investigational versions. Ongoing studies are examining the use of this drug in pediatric populations and for conditions other than the primary indication.

Frequently Asked Questions (FAQ)

Common questions about Epardex (FAQ)


Q: Is Epardex the same type of medicine as [similar sounding drug]?

Epardex contains the active ingredient Diclofenac, which is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This classification defines its specific chemical structure and how it works to reduce inflammation and pain in the body.


Q: Do I need to take Epardex with food or on an empty stomach?

Instructions depend on the specific form of the medicine. Official administration guidelines specify that the oral solution powder form must be taken on an empty stomach to optimize absorption. However, enteric-coated or delayed-release tablets may be taken with food, although this action may slightly delay the absorption of the drug.


Q: What is considered a common or expected side effect of Epardex?

Studies and official product information report that common adverse reactions are often related to the digestive system. These frequently include abdominal pain, indigestion (dyspepsia), nausea, flatulence, headache, and dizziness.


Q: Is Epardex safe to use for a long period of time?

Regulatory guidance emphasizes that this medicine should be used at the lowest effective dosage for the shortest duration possible. Potential risks, including serious cardiovascular and gastrointestinal adverse events, are documented to increase with the duration of use and higher doses, according to official warnings.


Q: How quickly does Epardex typically start to have an effect?

Onset of effect can be influenced by the specific formulation used. For example, the potassium salt formulation is noted for a faster rate of absorption compared to other salt forms, while taking certain tablets with food may delay absorption.


Q: Can Epardex cause changes in mood or sleep patterns?

Official drug documentation lists potential side effects that may affect the central nervous system. These can include effects like sleepiness, headache, and dizziness. Documentation notes that more serious or rare events involving changes in emotional state are also part of the medicine’s safety profile.


Q: Is Epardex considered a controlled substance?

No, Epardex (Diclofenac) is formally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and is not categorized as a controlled substance under federal or international drug schedules.


Q: Are there differences between the brand name and the generic version of Epardex?

Generic versions must demonstrate to regulatory authorities, such as the FDA, that they are bioequivalent to the brand-name product. This means they contain the exact same active ingredient, work the same way in the body, and are expected to have the same therapeutic effect.


Q: What if Epardex doesn't seem to be working for me after a few weeks?

The drug is prescribed for symptomatic management, and the individual response can vary. The core regulatory guidance emphasizes using the lowest effective dose for the shortest time. Therapeutic response can be evaluated by reviewing the initial treatment goals.


Q: Does Epardex affect or show up on standard lab tests?

Official warnings document potential adverse reactions that affect liver enzymes and kidney function (hepatotoxicity and renal toxicity). Due to this, regulatory documents often indicate the potential need for laboratory monitoring of these parameters during treatment.


Q: Is it true that Epardex can affect blood pressure?

Yes, official regulatory information documents that Epardex, like other NSAIDs, can cause new onset of hypertension (high blood pressure) or worsen pre-existing hypertension. It may also interfere with the effectiveness of certain medications taken for blood pressure.


Q: What happens when you stop taking Epardex?

Regulatory guidance states that there is typically no specific issue with stopping the medication in the short term. For long-term use in chronic conditions, a review of symptoms following cessation is important due to the potential return of the treated condition.


Q: How long after stopping Epardex does it stay in your system?

The active substance, Diclofenac, has a short plasma half-life, typically around 1 to 3 hours. The medicine is known to accumulate in the synovial fluid (joint fluid), and its presence there may persist longer than in the blood plasma.


Q: Does Epardex affect fertility?

Official documentation indicates that the use of this class of medication (NSAIDs) may be associated with a reversible delay or impairment of female fertility. This effect is usually temporary and resolves after the treatment is discontinued.


Q: What is the purpose of the different strengths (milligrams) of Epardex?

The availability of different strengths allows for precise dose titration. This enables authorized professionals to ensure the patient receives the lowest effective dose for their specific condition and risk profile, which is consistent with regulatory risk minimization strategies.


Q: Can people who are pregnant or breastfeeding use Epardex?

Use is generally advised against starting at about 20 weeks gestation and is formally contraindicated (must not be used) from 30 weeks onward due to the risk of fetal harm. Furthermore, the drug is known to be excreted in human milk, and its use is not recommended while breastfeeding.


Q: Can I take Epardex if I have a history of liver or kidney problems?

Epardex is formally contraindicated in patients with established hepatic failure or severe renal failure. For patients with mild to moderate impairment, official guidance strongly advises caution and close medical monitoring during treatment due to the risk of toxicity.


Q: What kind of professional is most likely to prescribe Epardex?

As a prescription-only medicine, Epardex is prescribed by authorized healthcare professionals who manage pain and inflammatory conditions. This includes general practitioners, rheumatologists, orthopedic specialists, and other clinicians.


Q: Is Epardex known to interact with herbal supplements?

Regulatory information advises caution regarding all complementary medicines and supplements. The regulatory principle is that complementary medicines are not tested for interaction in the same way as prescription drugs, and official information supports a review of all concomitant products.


Q: Is Epardex covered by most insurance plans?

Diclofenac, the active ingredient in Epardex, is a widely recognized and well-established drug. It is typically listed on the formularies of many health plans, often designated as a preferred generic option.


Q: What are the most frequently reported adverse events in studies of Epardex?

Official adverse reaction reports from clinical studies indicate that the most frequently reported events are related to the gastrointestinal system. These include nausea, diarrhea, vomiting, indigestion (dyspepsia), and abdominal pain.


Q: Do older adults (seniors) need to take a different amount of Epardex?

Official guidance recommends that treatment for older adults be initiated with the lowest available dose. While a specific dose reduction is not universally mandated, this precaution is advised due to the increased susceptibility of older patients to serious adverse events, particularly those affecting the stomach and kidneys.


Q: Are there any specific foods or drinks to avoid while taking Epardex?

Official warnings document that ingestion of alcohol increases the risk of gastric irritation and gastrointestinal bleeding. There are no other specific food groups that are universally restricted, though some formulations have specific requirements regarding whether they should be taken with food or on an empty stomach.


Q: Are there any specific warnings about driving or operating machinery while on Epardex?

Warnings are issued because of the potential for adverse effects such as dizziness, sleepiness, or visual disturbances. If a person experiences these effects, the official warnings caution against driving or operating complex machinery.


Q: What does 'clinical evidence' for Epardex actually mean?

Clinical evidence refers to the data generated from controlled human studies, such as randomized, placebo-controlled trials (RCTs). Regulatory bodies use this evidence to formally evaluate the drug's established benefits, documented risks, and appropriate conditions of use.

How should Epardex be stored and disposed of?

The storage and disposal of Epardex (Diclofenac) must follow the rules documented in regulatory labeling to maintain stability.

Official Storage Requirements

Condition Requirement
Temperature Store in a cool place, generally not above 30 C or 25 C.
Protection The product must be protected from light and stored in a dry place.
Container Keep the medication tightly closed in its original container.
Child Safety Keep out of the sight and reach of children.

Official Disposal Rules

Unused or expired Epardex must not be disposed of by flushing it down the toilet or putting it in household trash. Disposal must occur through local pharmaceutical waste regulations and official take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Epardex found in:

A-Z Index: